Author at Microdose

Alexa Julianne

Alexa Julianne works at MAPS to support MDMA-assisted therapy for the treatment of PTSD. With a professional background as a clinical lab scientist, she also has a comprehensive understanding of the many recent and ongoing clinical trials investigating the medical use of all psychedelics. As a writer, she provides research-based educational articles about the therapeutic potential of psychedelics. She is an advocate of psychedelic-assisted therapy for mental health, wellness, and healing and continues to support the advancement of psychedelic clinical research.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Science

30 Aug 2022

Science Feature: Psilocybin for Headaches

With mounting evidence to support the use of psychedelics in treating serious disorders like PTSD, depression, and anxiety — the sector is now beginning to focus on more highly specialized...

By Alexa Julianne

Science

27 May 2022

Combining Antidepressants and Psilocybin: A Look at the Research

Although it’s too early to say whether patients should taper off antidepressants or combine them with psilocybin treatment, research suggests it may be possible to combine the two...

By Alexa Julianne

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

Alexa Julianne works at MAPS to support MDMA-assisted therapy for the treatment of PTSD. With a professional background as a clinical lab scientist, she also has a comprehensive understanding of the many recent and ongoing clinical trials investigating the medical use of all psychedelics. As a writer, she provides research-based educational articles about the therapeutic potential of psychedelics. She is an advocate of psychedelic-assisted therapy for mental health, wellness, and healing and continues to support the advancement of psychedelic clinical research.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads